Abstract
Acute myeloid leukemia (AML) is a malignant disease of the bone marrow. Despite intensive treatment only one third of AML patients are cured. Numerous genetic events have been identified in the last years that have shed light into the mechanisms dictating increased self-renewal, proliferation, survival and block in differentiation. It is increasingly recognized that AML represents a hierarchical disease, originating from a leukemia stem cell population. Sophisticated animal models have helped to elucidate rate-limiting steps in initiation, development and maintenance of AML. This review discusses the fundamental genetic events identified to date that determine the pathogenesis of AML, with particular emphasis on the oncogenic signaling events that result from translocation of myeloid transcription factors and mutations in receptor tyrosine kinases. Our current understanding of the biology of AML has fueled the development of promising anti-leukemic agents, which may improve the treatment of the disease in the future.
Keywords: Acute promyelocytic leukemia (APL), core binding factor (CBF), GATA-1 mutation, Nucleophosmin (NPM), MLL protein, Hox homeodomain proteins
Current Drug Targets
Title: Oncogenic Signaling in Acute Myeloid Leukemia
Volume: 8 Issue: 2
Author(s): Christian H. Brandts, Wolfgang E. Berdel and Hubert Serve
Affiliation:
Keywords: Acute promyelocytic leukemia (APL), core binding factor (CBF), GATA-1 mutation, Nucleophosmin (NPM), MLL protein, Hox homeodomain proteins
Abstract: Acute myeloid leukemia (AML) is a malignant disease of the bone marrow. Despite intensive treatment only one third of AML patients are cured. Numerous genetic events have been identified in the last years that have shed light into the mechanisms dictating increased self-renewal, proliferation, survival and block in differentiation. It is increasingly recognized that AML represents a hierarchical disease, originating from a leukemia stem cell population. Sophisticated animal models have helped to elucidate rate-limiting steps in initiation, development and maintenance of AML. This review discusses the fundamental genetic events identified to date that determine the pathogenesis of AML, with particular emphasis on the oncogenic signaling events that result from translocation of myeloid transcription factors and mutations in receptor tyrosine kinases. Our current understanding of the biology of AML has fueled the development of promising anti-leukemic agents, which may improve the treatment of the disease in the future.
Export Options
About this article
Cite this article as:
Brandts H. Christian, Berdel E. Wolfgang and Serve Hubert, Oncogenic Signaling in Acute Myeloid Leukemia, Current Drug Targets 2007; 8 (2) . https://dx.doi.org/10.2174/138945007779940197
DOI https://dx.doi.org/10.2174/138945007779940197 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents on Peptide Self-Assembled Hydrogels as Nanostructured Biomaterials
Recent Patents on Nanomedicine Pyrimidine Nucleosides in Molecular PET Imaging of Tumor Proliferation
Current Medicinal Chemistry Lipid-based Nanocarriers Loaded with Taxanes for the Management of Breast Cancer: Promises and Challenges
Current Drug Targets New Perspectives of HIV/AIDS Therapy Study
Recent Patents on Anti-Infective Drug Discovery Particle-based Vaccines for HIV-1 Infection
Current Drug Targets - Infectious Disorders Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
Current Drug Discovery Technologies Signal Transduction in HIV Protein-Treated Astrocytes
Current Signal Transduction Therapy Nano-Enabled Drug Delivery in Cancer Therapy: Literature Analysis Using the MeSH System
Pharmaceutical Nanotechnology EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors
Current Topics in Medicinal Chemistry Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets CD44 and EpCAM: Cancer-Initiating Cell Markers
Current Molecular Medicine Molecular Modelling and QSAR in the Discovery of HIV-1 Integrase Inhibitors
Current Computer-Aided Drug Design In Vivo Application and Tracking of Baculovirus
Current Gene Therapy TNF α Signaling Beholds Thalidomide Saga: A Review of Mechanistic Role of TNF-α Signaling Under Thalidomide
Current Topics in Medicinal Chemistry Mesenchymal Stem Cells: Use in Cartilage Repair
Current Rheumatology Reviews The Role of CD8+ T Cell Soluble Factors in Human Immunodeficiency Virus Infection
Current Medicinal Chemistry Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Gene Therapeutic Approaches for Immune Modulation in AIDS
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery